Blog

LongeVC's Artemy Shumskiy as the Panel Speaker at the SCOPE Europe Conference in Barcelona on October 29-30

The EU AI Act represents a pivotal change in the European tech landscape, aiming to regulate the development and use of artificial intelligence across sectors. For biotech firms, the Act introduces compliance challenges, operational shifts, and new obligations. It requires a strategic approach that aligns with regulatory requirements while maintaining innovation in AI applications within biotech.

This topic will be the center of discussion at the upcoming SCOPE Europe on October 30. Our senior associate, Artemy Shumskiy, will join a panel to dive into the Act’s implications, particularly for biotech. The conversation will feature experts, including Ricardo Gaminha Pacheco from Insilico Medicine, Firas Abdessalem from Sanofi, Christopher Hart from Foley Hoag LLP, and Gandolf Finke from Mika Health by Fosanis GmbH. Barnaby Pickering from Citeline will moderate the discussion.

The panel will address how biotech companies can navigate compliance with the new AI regulations, what day-to-day operational changes are expected, and how to mitigate potential risks while ensuring ongoing innovation in the field.

For more information about the event, visit the website here.

If you're planning to attend SCOPE Europe in Barcelona and would like to connect with our team, please email us at hq@longevc.com or reach out to Artemy directly.
Announcement